CD274 and head and neck squamous cell carcinoma: The results of the final analysis suggested that the use of pembrolizumab in PD-L1-positive R/M HNSCC, either as monotherapy or in combination with chemotherapy, was preferred to treatment with EXTREME schedule, considered the standard of care from 2008 to 2019.